Premium
Intranasal CpG‐Oligodeoxynucleotide is a Potent Adjuvant of Vaccine against Helicobacter pylori , and T Helper 1 Type Response and Interferon‐γ Correlate with the Protection
Author(s) -
Shi Tong,
Liu Wenzhong,
Gao Fei,
Shi Guiying,
Xiao Shudong
Publication year - 2005
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/j.1523-5378.2005.00293.x
Subject(s) - cpg oligodeoxynucleotide , adjuvant , helicobacter pylori , nasal administration , immunology , vaccination , antibody , medicine , biology , dna methylation , biochemistry , gene expression , gene
Background. Although a series of vaccines against Helicobacter pylori have emerged in the past 10 years, the mechanism involved in their protective effect is yet to be elucidated, and more effective vaccine adjuvants remain to be developed. In this study, CpG‐oligodeoxynucleotide (CpG‐ODN) was investigated as a new candidate for a H. pylori vaccine adjuvant. Furthermore, the role of T helper 1 (Th1) type response and interferon (IFN)‐γ in the protective immunity was explored. Methods. C57BL/6 mice and IFN‐γ knockout mice were intranasally or orally immunized with H. pylori whole cell sonicate (WCS)/CpG‐ODN and challenged with different doses [5 × 10 8 and 5 × 10 6 colony‐forming units (CFU)] of H. pylori . The protective effect was assessed as the percentage of noninfected mice. The responsive antibodies and cytokines were analyzed using an enzyme‐linked immunosorbent assay (ELISA) and flow cytometry. Results. The prevention rates against H. pylori infection in mice intranasally immunized with WCS plus CpG‐ODN were dramatically higher than those in sham‐immunized mice (70% vs. 0%, challenged with 5 × 10 8 CFU H. pylori ; 90% vs. 20%, challenged with 5 × 10 6 CFU H. pylori ). Significantly higher levels of immunoglobulin G2a (IgG2a) and IFN‐γ were detected in the mice immunized with WCS/CpG than in sham‐immunized controls. However, vaccination failed to effectively protect IFN‐γ knockout mice challenged with H. pylori . Conclusions. CpG‐ODN given intranasally is a potent adjuvant for development of a H. pylori vaccine. Th1‐type response and IFN‐γ are involved in the protection.